title: Comparative effectiveness of torsemide versus furosemide in heart failure patients: insights from the PROTECT trial.
abstract: OBJECTIVE
  The authors assessed the comparative effectiveness of torsemide versus furosemide in the PROTECT trial.
  
  
  METHODS
  The authors assessed the relationship between loop diuretic at discharge and death or cardiovascular/renal hospitalization within 30 days, and death through 150 days postdischarge using inverse probability weighting.
  
  
  RESULTS
  Out of 1004 patients, 83.5% received furosemide and 16.5% torsemide. Torsemide patients had higher blood urea nitrogen, and more in-hospital worsening heart failure. Following adjustment, torsemide was associated with similar 30-day outcomes compared with furosemide (p = 0.93), but remained associated with increased 150-day death (hazard ratio: 2.26; 95% CI: 1.40-3.66; p < 0.001).
  
  
  CONCLUSIONS
  Patients treated with torsemide had features of greater disease severity, similar 30-day outcomes but increased 150-day mortality. Prospective randomized trials are needed to investigate the effect of torsemide versus furosemide.
authors.affiliation: Duke University, Durham, NC 27708, USA.|Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715, USA.
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Mentz
authors.affiliation: Duke University, Durham, NC 27708, USA.|Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715, USA.
authors.forename: Eric J
authors.initials: EJ
authors.lastname: Velazquez
authors.affiliation: University of Brescia, Piazza del Mercato, 15, Brescia BS, Italy.
authors.forename: Marco
authors.initials: M
authors.lastname: Metra
authors.affiliation: Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715, USA.
authors.forename: Colleen
authors.initials: C
authors.lastname: McKendry
authors.affiliation: Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715, USA.
authors.forename: Karen
authors.initials: K
authors.lastname: Chiswell
authors.affiliation: Duke University, Durham, NC 27708, USA.|Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715, USA.
authors.forename: Mona
authors.initials: M
authors.lastname: Fiuzat
authors.affiliation: Brigham & Women's Hospital, 75 Francis St, Boston, MA 02115, USA.
authors.forename: Michael M
authors.initials: MM
authors.lastname: Givertz
authors.affiliation: University of Groningen, 9712 CP Groningen, The Netherlands.
authors.forename: Adriaan A
authors.initials: AA
authors.lastname: Voors
authors.affiliation: University of California at San Francisco (SF) & SF Veterans Affairs Medical Center, 500 Parnassus Ave, San Francisco, CA 94143, USA.
authors.forename: John R
authors.initials: JR
authors.lastname: Teerlink
authors.affiliation: Duke University, Durham, NC 27708, USA.|Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715, USA.
authors.forename: Christopher M
authors.initials: CM
authors.lastname: O'Connor
mesh_terms: D000368:Aged; D018450:Disease Progression; D004232:Diuretics / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D005060:Europe / Q000453:epidemiology; D005260:Female; D005500:Follow-Up Studies; D005665:Furosemide / Q000008:administration & dosage*; D006333:Heart Failure / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D013449:Sulfonamides / Q000008:administration & dosage*; D015996:Survival Rate / Q000639:trends; D013997:Time Factors; D000077786:Torsemide; D016896:Treatment Outcome
chemical_list: D004232:Diuretics; D013449:Sulfonamides; D005665:Furosemide; D000077786:Torsemide
keywords: furosemide; heart failure; loop diuretics; outcomes; torsemide